In spite of consistent progress at the level of basic research and of clinical treatment, acute
myeloid leukemia (AML) still represents an unmet clinical need for adult and pediatric …

Therapeutic cancer vaccines have been a subject of research for several decades as
potential new weapons to tackle malignancies. Their goal is to induce a long-lasting and …

Acute myeloid leukemia (AML) is a very heterogeneous hematological malignancy that
accounts for approximately 20% of all pediatric leukemia cases. The outcome of pediatric …

Acute myeloid leukemia (AML) is the most aggressive adult leukemia, characterized by
clonal differentiation arrest of progenitor or precursor hematopoietic cells. Intense preclinical …

Simple Summary Despite increasing knowledge of the biological mechanisms leading to
neoplastic transformation, the identification of various molecular targets for innovative drugs …

In the last twenty years, we have witnessed a paradigm shift in the treatment and prognosis
of acute myeloid leukemia (AML), thanks to the introduction of new efficient drugs or …

T-cell redirecting therapies (TCRTs), such as CAR-or TCR T-cells and T-cell engagers, have
emerged as a highly effective treatment modality, particularly in the B-and plasma cell …

Recurrent and/or refractory (R/R) pediatric acute myeloid leukemia (AML) remains a
recalcitrant disease with poor outcomes. Cell therapy with genetically modified immune …

AML is a malignant disease of hematopoietic progenitor cells with unsatisfactory treatment
outcome, especially in patients that are ineligible for intensive chemotherapy …

Chimeric antigen receptor (CAR) T therapies are being developed for acute myeloid
leukemia (AML) on the basis of the results obtained for other haematological malignancies …